StockGuru Blog: The Immune Response Corporation – IncreMental Advantage Research Report States Immune Response Could Become Quite Profitable Even With Low Market Penetration Rates
The Immune Response Corporation Symbol: IMNR - StockGuru Profile IMNR IncreMental Advantage, an equity research firm, has initiated coverage of The Immune Response Corporation (OTCBB: IMNR) with an accumulate rating and a price target of $.09 per share, substantially above the current per share price. IncreMental Advantage IMNR Research Report IncreMental Advantage’s research report on The Immune Response Corporation is available at http://www.roiny.com/clients-irc-research.php . This report indicates that Immune Response could become quite profitable even with low market penetration rates. Revenues and Earnings Estimates The markets for the Immune Response Corporation’s products are so large that a successful product would…